title: NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.
abstract: Several reports demonstrated that the activation of Nuclear Factor-kappa B NF-κB is essential for the pathogenesis of multiple myeloma (MM). We analyzed the nuclear localization of NF-κB in MM-cells derived from 60 different patients with MM at presentation and in relapse, as well as in three myeloma cell lines. Nuclear localization (the active form) of NF-κB was detected in only one MM-sample from a refractory patient and in two samples from relapsed patients, while all the other samples, including the MM-cell lines, almost exclusively express the cytoplasmic (inactive) form of NF-κB. In mesenchymal cells from MM-patients NF-κB was clearly present in the nucleus. In addition, the proteasome inhibitor Bortezomib, which is described to antagonize NF-κB activity, had a consistent antitumor activity against both chemoresistant and chemosensitive MM-cells, regardless the NF-κB localization, thus suggesting the existence of other molecular targets of proteasome inhibitors in MM.
authors.affiliation: Department of Experimental Oncology, Mediterranean Institute of Oncology (IOM), Viagrande, Catania, Italy.
authors.forename: Concetta
authors.initials: C
authors.lastname: Conticello
authors.forename: Raffaella
authors.initials: R
authors.lastname: Giuffrida
authors.forename: Luana
authors.initials: L
authors.lastname: Adamo
authors.forename: Gabriele
authors.initials: G
authors.lastname: Anastasi
authors.forename: Daniela
authors.initials: D
authors.lastname: Martinetti
authors.forename: Edvige
authors.initials: E
authors.lastname: Salomone
authors.forename: Cristina
authors.initials: C
authors.lastname: Colarossi
authors.forename: Gabriella
authors.initials: G
authors.lastname: Amato
authors.forename: Ausilia
authors.initials: A
authors.lastname: Gorgone
authors.forename: Alessandra
authors.initials: A
authors.lastname: Romano
authors.forename: Gioacchin
authors.initials: G
authors.lastname: Iannolo
authors.forename: Ruggero
authors.initials: R
authors.lastname: De Maria
authors.forename: Rosario
authors.initials: R
authors.lastname: Giustolisi
authors.forename: Massimo
authors.initials: M
authors.lastname: Gulisano
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D015153:Blotting, Western; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D045744:Cell Line, Tumor; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D008648:Mesoderm / Q000378:metabolism* / Q000473:pathology; D009101:Multiple Myeloma / Q000378:metabolism* / Q000473:pathology; D016328:NF-kappa B / Q000378:metabolism*; D010950:Plasma Cells / Q000378:metabolism*; D011719:Pyrazines / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D016328:NF-kappa B; D011719:Pyrazines; D000069286:Bortezomib